Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONCY Oncolytics Biotech Inc

Trading 02-13 13:51:17 EST

1.03

+0.19

+22.80%

High1.04	Low0.8352	Vol2.76M
Open0.8890	D1 Closing0.8347	Amplitude24.54%
Mkt Cap110.70M	Tradable Cap108.65M	Total Shares108.00M
T/O2.60M	T/O Rate2.61%	Tradable Shares106.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ONCY","market":"US","secType":"STK","nameCN":"Oncolytics Biotech Inc","latestPrice":1.025,"timestamp":1771008676153,"preClose":0.8347,"halted":0,"volume":2762237,"delay":0,"changeRate":0.22798610279142195,"floatShares":106000000,"shares":108000000,"eps":-0.285545,"marketStatus":"Trading","change":0.1903,"latestTime":"02-13 13:51:17 EST","open":0.889,"high":1.04,"low":0.8352,"amount":2599060.16950408,"amplitude":0.245358,"askPrice":1.03,"askSize":3990,"bidPrice":1.02,"bidSize":471,"shortable":3,"etf":0,"ttmEps":-0.285545,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771016400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1002254400000,"exchange":"NASDAQ","adjPreClose":0.8347,"preHourTrading":{"tag":"盘前","latestPrice":0.87,"preClose":0.8347,"latestTime":"09:25 EST","volume":220488,"amount":190307.0072424,"timestamp":1770992745999,"change":0.0353,"changeRate":0.042291,"amplitude":0.039415},"postHourTrading":{"tag":"盘后","latestPrice":0.8344,"preClose":0.8347,"latestTime":"19:59 EST","volume":3457,"amount":2877.4332,"timestamp":1770944375621,"change":-0.0003,"changeRate":-0.000359,"amplitude":0.019887},"volumeRatio":2.969218},"requestUrl":"/m/hq/s/ONCY","defaultTab":"news","newsList":[{"id":"2611159082","title":"Director Bernd R. Seizinger Reports Acquisition of Oncolytics Biotech Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611159082","media":"Reuters","labels":["insiderTrades","express"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2611159082?lang=en_us&edition=fundamental","pubTime":"2026-02-13 20:01","pubTimestamp":1770984064,"startTime":"0","endTime":"0","summary":"Bernd R. Seizinger, Director at Oncolytics Biotech Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL9VgTwq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Bernd R. Seizinger Reports Acquisition of Oncolytics Biotech Inc. Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"gpt_icon":0},{"id":"2611159069","title":"Oncolytics Biotech Director Deborah Margaret Brown Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611159069","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611159069?lang=en_us&edition=fundamental","pubTime":"2026-02-13 20:01","pubTimestamp":1770984072,"startTime":"0","endTime":"0","summary":"Deborah Margaret Brown, Director at Oncolytics Biotech Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL7lZcpP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2611041159","title":"Director Wayne Pisano Acquires Common Shares of Oncolytics Biotech Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2611041159","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611041159?lang=en_us&edition=fundamental","pubTime":"2026-02-13 20:01","pubTimestamp":1770984070,"startTime":"0","endTime":"0","summary":"Wayne Pisano, Director, reported the acquisition of common shares of Oncolytics Biotech Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL7sXcK2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"gpt_icon":0},{"id":"2611590271","title":"Allison Hagerman, VP Product Development, Reports Acquisition of Oncolytics Biotech Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611590271","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611590271?lang=en_us&edition=fundamental","pubTime":"2026-02-13 20:01","pubTimestamp":1770984067,"startTime":"0","endTime":"0","summary":"Allison Hagerman, Vice President of Product Development, reported the acquisition of common shares of Oncolytics Biotech Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL9g7HNt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2609971365","title":"Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Oncolytics Biotech (ONCY) and Imunon (IMNN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609971365","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609971365?lang=en_us&edition=fundamental","pubTime":"2026-02-06 23:30","pubTimestamp":1770391848,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insmed (INSM – Research Report), Oncolytics Biotech ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-insmed-insm-oncolytics-biotech-oncy-and-imunon-imnn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-insmed-insm-oncolytics-biotech-oncy-and-imunon-imnn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","XLV","LU0128526141.USD","XBI","HCSG","BK4139","LU0320765992.SGD","LU0109394709.USD","IMNN","BK4588","BK4581","BK4137","BK4585","LU0029874061.USD","ONCY","LABU","LU0053671581.USD","INSM"],"gpt_icon":0},{"id":"2609309931","title":"Oncolytics Biotech Appoints John McAdory and Yujun Wu to Leadership Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2609309931","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609309931?lang=en_us&edition=fundamental","pubTime":"2026-02-05 22:26","pubTimestamp":1770301579,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc. has announced two new leadership appointments: John McAdory joins as Executive Vice President of Strategy and Operations, and Yujun Wu becomes Vice President, Head of Biostatistics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL8gW0pc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","SG9999014021.USD","IE00B64PRP62.GBP","ONCY","BK4139","SG9999014013.SGD","SG9999014039.USD","LU2210149790.SGD","NDAQ","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014005.SGD","IE00BKPKM429.USD","BK4588","LU0314104364.USD"],"gpt_icon":0},{"id":"2608367402","title":"Oncolytics receives FDA Fast Track Designation for pelareorep","url":"https://stock-news.laohu8.com/highlight/detail?id=2608367402","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608367402?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:55","pubTimestamp":1770213327,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) Biotech announced that the U.S. Food and Drug Administration has granted Fast Track Designation to pelareorep in combination with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-receives-fda-fast-track-designation-for-pelareorep-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-receives-fda-fast-track-designation-for-pelareorep-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ONCY","BK4585","BK4588","LABU"],"gpt_icon":0},{"id":"2608367325","title":"FDA Grants Fast Track Designation to Oncolytics Biotech's Pelareorep for KRAS-Mutant MSS Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2608367325","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608367325?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:50","pubTimestamp":1770213014,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc. announced that the U.S. Food and Drug Administration  has granted Fast Track Designation to pelareorep in combination with bevacizumab  and FOLFIRI for the treatment of patients with KRAS-mutant, microsatellite-stable metastatic colorectal cancer in the second-line setting. The company plans to initiate a controlled clinical study comparing standard-of-care therapy alone versus standard-of-care plus pelareorep, with interim data expected by the end of 2026. This designation is intended to facilitate the development and expedite the review of therapies that address unmet medical needs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL1H35ch:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","LU0314104364.USD","BK4139","LU2210150020.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD","SG9999014021.USD","SG9999014005.SGD","NDAQ","BK4588","ONCY","IE00B64PRP62.GBP","BK4585","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2608367872","title":"Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L Kras-Mutant Mss Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2608367872","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608367872?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:50","pubTimestamp":1770213000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nTUAC63QT8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCY"],"gpt_icon":0},{"id":"2608367322","title":"Oncolytics Biotech Inc - to Launch Controlled Study in Second-Line Kras-Mutant Mss Mcrc With Interim Data Expected by End of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2608367322","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608367322?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:50","pubTimestamp":1770213000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nTUAC63QT8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2605481145","title":"Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605481145","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605481145?lang=en_us&edition=fundamental","pubTime":"2026-01-22 00:40","pubTimestamp":1769013615,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Trevi Therapeutics (TRVI – Research Report), Artiva ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-trevi-therapeutics-trvi-artiva-biotherapeutics-inc-artv-and-oncolytics-biotech-oncy-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-trevi-therapeutics-trvi-artiva-biotherapeutics-inc-artv-and-oncolytics-biotech-oncy-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTV","ONCY","BK4585","BK4007","BK4137","BK4588","LABU","XLV","BK4581","XBI","HCSG","BK4139","LU0029874061.USD","TRVI","LU0128526141.USD"],"gpt_icon":0},{"id":"2605419641","title":"Oncolytics Biotech Director Bernd R. Seizinger Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605419641","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605419641?lang=en_us&edition=fundamental","pubTime":"2026-01-21 05:31","pubTimestamp":1768944674,"startTime":"0","endTime":"0","summary":"Bernd R. Seizinger, Director at Oncolytics Biotech Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL50HRgC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Oncolytics Biotech Director Bernd R. Seizinger Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2603935685","title":"Oncolytics Biotech Inc. Held Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2603935685","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603935685?lang=en_us&edition=fundamental","pubTime":"2026-01-16 05:01","pubTimestamp":1768510885,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc. held a Special Meeting of Shareholders on January 15, 2026. Shareholders approved a proposal to continue the company from the Province of Alberta to the Province of British Columbia in Canada, and another proposal to continue the company from the Province of British Columbia to the State of Nevada in the United States. In addition, shareholders approved the implementation of the Oncolytics Biotech Inc. 2026 Incentive Award Plan, conditional upon completion of the continuance and domestication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire  on January 15, 2026, and is solely responsible for the information c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDLxhHpB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","NDAQ","ONCY","SG9999014005.SGD","BK4588","SG9999014013.SGD","SG9999014039.USD","IE00BKPKM429.USD","BK4585","LU2095319765.USD","IE00B3QW5Z07.USD","BK4139","LU2210149790.SGD","LU0314104364.USD","BK4112","SG9999014021.USD","IE00BGHQF748.EUR","LU2210150020.SGD"],"gpt_icon":0},{"id":"2603611437","title":"Oncolytics Biotech Appoints John McAdory as EVP of Strategy and Yujun Wu as Head of Biostatistics","url":"https://stock-news.laohu8.com/highlight/detail?id=2603611437","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603611437?lang=en_us&edition=fundamental","pubTime":"2026-01-14 22:01","pubTimestamp":1768399317,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc. has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. McAdory will oversee clinical development execution and operational strategy, while Wu will lead biostatistics and statistical strategy for the company’s clinical programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire  on January 14, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL2k4DFh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BGHQF748.EUR","SG9999014013.SGD","ONCY","BK4588","BK4585","BK4139","BK4112","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU2210149790.SGD","NDAQ","LU2210150020.SGD","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","SG9999014021.USD"],"gpt_icon":0},{"id":"2603633792","title":"Lake Street Reaffirms Their Buy Rating on Oncolytics Biotech (ONCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603633792","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603633792?lang=en_us&edition=fundamental","pubTime":"2026-01-13 23:17","pubTimestamp":1768317438,"startTime":"0","endTime":"0","summary":"In a report released today, Chad Messer from Lake Street maintained a Buy rating on Oncolytics Biotech, with a price target of $7.00. According to ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lake-street-reaffirms-their-buy-rating-on-oncolytics-biotech-oncy-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lake-street-reaffirms-their-buy-rating-on-oncolytics-biotech-oncy-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONCY"],"gpt_icon":0},{"id":"2602543221","title":"Oncolytics Biotech Reports Pelareorep Plus Atezolizumab Triples Response Rate in Third-Line Anal Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543221","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543221?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:01","pubTimestamp":1768226476,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc. announced updated clinical data from the GOBLET Cohort 4 study evaluating the combination of pelareorep and atezolizumab in patients with third-line metastatic squamous cell anal carcinoma , a setting with no FDA-approved treatment options. The results, already presented, showed an objective response rate  of approximately 29%, with two complete responses and two partial responses among 14 evaluable patients. The median duration of response  was approximately 17 months. These outcomes compare favorably to historical third-line SCAC studies, which report ORRs of around 10% or less. Oncolytics Biotech plans to meet with the FDA in Q1 2026 to discuss a potential registration strategy and the possibility of seeking accelerated approval for this indication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informationa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLbfTRHS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014013.SGD","ONCY","LU2095319765.USD","BK4585","BK4112","LU2210150020.SGD","BK4588","SG9999014005.SGD","SG9999014021.USD","BK4139","IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","SG9999014039.USD"],"gpt_icon":0},{"id":"2602554325","title":"Oncolytics Biotech Inc - Four of 14 Third-Line Patients Achieved Objective Responses","url":"https://stock-news.laohu8.com/highlight/detail?id=2602554325","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602554325?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:00","pubTimestamp":1768226408,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7W5N5F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2602543288","title":"Oncolytics Biotech® Announces Updated Clinical Data From Goblet Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543288","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543288?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:00","pubTimestamp":1768226408,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7W5N5F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2602432345","title":"Oncolytics Biotech Inc - Plans Type C Meeting With FDA in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602432345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602432345?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:00","pubTimestamp":1768226408,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7W5N5F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2602054323","title":"Oncolytics Biotech Inc - Median Duration of Response About 17 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2602054323","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602054323?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:00","pubTimestamp":1768226408,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7W5N5F:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oncolyticsbiotech.com","stockEarnings":[{"period":"1week","weight":-0.0023},{"period":"1month","weight":-0.1653},{"period":"3month","weight":-0.1974},{"period":"6month","weight":-0.2271},{"period":"1year","weight":0.0682},{"period":"ytd","weight":-0.045}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":-0.018},{"period":"3month","weight":0.0139},{"period":"6month","weight":0.0588},{"period":"1year","weight":0.1291},{"period":"ytd","weight":-0.001}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.001975},{"month":2,"riseRate":0.125,"avgChangeRate":-0.062685},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.105719},{"month":4,"riseRate":0.714286,"avgChangeRate":0.022868},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.009291},{"month":6,"riseRate":0.285714,"avgChangeRate":0.190573},{"month":7,"riseRate":0.5,"avgChangeRate":0.009647},{"month":8,"riseRate":0.25,"avgChangeRate":-0.092405},{"month":9,"riseRate":0.125,"avgChangeRate":-0.025103},{"month":10,"riseRate":0.5,"avgChangeRate":0.144514},{"month":11,"riseRate":0.25,"avgChangeRate":0.020161},{"month":12,"riseRate":0.125,"avgChangeRate":0.270533}],"exchange":"NASDAQ","name":"Oncolytics Biotech Inc","nameEN":"Oncolytics Biotech Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oncolytics Biotech Inc,ONCY,Oncolytics Biotech Inc股票,Oncolytics Biotech Inc股票老虎,Oncolytics Biotech Inc股票老虎国际,Oncolytics Biotech Inc行情,Oncolytics Biotech Inc股票行情,Oncolytics Biotech Inc股价,Oncolytics Biotech Inc股市,Oncolytics Biotech Inc股票价格,Oncolytics Biotech Inc股票交易,Oncolytics Biotech Inc股票购买,Oncolytics Biotech Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction